Drugs / CFH protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07567235 | Jun 2026 → Mar 2027 expected | head and neck squamous cell carcinoma, radiation-induced disorder | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CFH protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07567235 ↗ |
| Known as | complement factor H | “intradermal delivery of complement factor H (CFH) fragment (human, 860-1231aa) via ice microneedles” NCT07567235 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human CFH protein delivered intradermally via ice microneedle patches” NCT07567235 ↗ |